Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| humanized origin | 5759 | 953400-68-5 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Lebrikizumab is an immunoglobulin (IgG4) monoclonal antibody that binds with high affinity to interleukin (IL)-13 and selectively inhibits IL-13 signalling through the IL-4 receptor alpha (IL-4Ralpha)/ IL-13 receptor alpha 1 (IL-13Ralpha1) heterodimer, thereby inhibiting the downstream effects of IL-13. Inhibition of IL-13 signalling is expected to be of benefit in diseases in which IL-13 is a key contributor to the disease pathogenesis. Lebrikizumab does not prevent the binding of IL-13 to the IL-13 receptor alpha 2 (IL-13Ralpha2 or decoy receptor), which allows the internalisation of IL-13 into the cell.
|
| Dose | Unit | Route |
|---|---|---|
| 8.90 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 16, 2023 | EMA | ALMIRALL, S.A. |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dermatitis atopic | 91.64 | 66.69 | 21 | 371 | 23451 | 90604604 |
| Pruritus | 80.69 | 66.69 | 41 | 351 | 541484 | 90086571 |
| Dry skin | 76.54 | 66.69 | 24 | 368 | 88049 | 90540006 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Dermatitis atopic | 87.79 | 57.65 | 20 | 387 | 25521 | 110563371 |
| Pruritus | 75.09 | 57.65 | 38 | 369 | 581522 | 110007370 |
| Eczema | 71.54 | 57.65 | 21 | 386 | 72272 | 110516620 |
| Dry skin | 67.35 | 57.65 | 22 | 385 | 107631 | 110481261 |
None
| Source | Code | Description |
|---|---|---|
| ATC | D11AH10 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids |
| FDA EPC | N0000193985 | Interleukin-13 Antagonist |
| FDA MoA | N0000193986 | Interleukin-13 Antagonists |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Moderate to severe atopic dermatitis | indication | 24079001 | DOID:3310 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Interleukin-13 | Cytokine | INHIBITOR | Kd | 9.73 | SCIENTIFIC LITERATURE | DRUG LABEL |
| ID | Source |
|---|---|
| CHEMBL1743035 | ChEMBL_ID |
| C561806 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7684 | IUPHAR_LIGAND_ID |
| DB11914 | DRUGBANK_ID |
| 4043406 | VANDF |
| C2981360 | UMLSCUI |
| CHEBI:750113 | CHEBI |
| 9165 | INN_ID |
| 43079 | MMSL |
| d10214 | MMSL |
| U9JLP7V031 | UNII |
| 2693758 | RXNORM |
| 1351535000 | SNOMEDCT_US |
| D09633 | KEGG_DRUG |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| EBGLYSS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-7772 | INJECTION, SOLUTION | 250 mg | SUBCUTANEOUS | BLA | 30 sections |
| EBGLYSS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-7797 | INJECTION, SOLUTION | 250 mg | SUBCUTANEOUS | BLA | 30 sections |